| Description | Adrenocorticotropic Hormone (ACTH) (4-10) TFA (Acth (4-10)) is an agonist of potent melanocortin(MC4R) receptor . |
| In vivo | In humans, Adrenocorticotropic Hormone (ACTH) (4-10)?enters the cerebral fluid compartment after intranasal application and leads to a?decrease in total body fat after 6 weeks of continuous treatment[1]. |
| Synonyms | Adrenocorticotropic Hormone (ACTH) (4-10) TFA(4037-01-8(free base)), Acth (4-10) |
| molecular weight | 1076.12 |
| Molecular formula | C46H60F3N13O12S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/ml (51.11 mM) |
| References | 1. P Wellhöner, R Hörster, Jacobs F , et al. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue.[J]. International Journal of Obesity, 2012, 36(5):703. 2. Krude H , Biebermann H , Schnabel D , et al. Obesity Due to Proopiomelanocortin Deficiency: Three New Cases and Treatment Trials with Thyroid Hormone and ACTH4–10[J]. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(10):4633-4640. |